SEC Form 4 · accession 0001209191-18-002556
Regulus Therapeutics Inc. · RGLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy Michael Wright
Officer — Chief R & D Officer
Period of report
Jan 5, 2018
Accepted (ET)
Jan 5, 2018 · 6:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001505512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.24 | Jan 5, 2018 | A | 500,000 | A | — | Jan 4, 2028 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1The option will vest in forty-eight equal monthly installments, such that the option will be fully vested four years from the date of grant, subject to the Reporting Person's continuous service to us.